【产品介绍】：

中文别名 利巴韦林(cas:36791-04-5);1-beta-D-呋喃核糖基-1H-1,2,4,-三氮唑-3-羧酰胺; 利巴韦林; 1-B-D呋喃核糖-1,2,4-三氮唑-3-羟酰胺; 病毒唑; 三氮唑核苷; 1-β-D-呋喃核糖-1,2,4-三氮唑-3-羟酰胺; 三氨唑核苷; 1-Β-D-呋喃核糖苷-1H-1,2,4-三氮唑-3-羧酰胺; 三唑核苷; 酰胺三嗪核苷 英文别名 Ribavirin(cas:36791-04-5),ribavirin, Ribasphere, Ribavirine, Ribavirina, Ribavirinum CAS号 36791-04-5 SMILES O[C@H]1[C@H](N2N=C(C(N)=O)N=C2)O[C@H](CO)[C@H]1O Inchi InChI=1S/C8H12N4O5/c9-6(16)7-10-2-12(11-7)8-5(15)4(14)3(1-13)17-8/h2-5,8,13-15H,1H2,(H2,9,16)/t3-,4-,5-,8-/m1/s1 InchiKey IWUCXVSUMQZMFG-AFCXAGJDSA-N 分子式 Formula C8H12N4O5 分子量 Molecular Weight 244.2 闪点 FP 340.7±34.3 °C 熔点 Melting point 175 °C 沸点 Boiling point 639.8±65.0 °C at 760 mmHg Polarizability极化度 20.3±0.5 10-24cm3 密度 Density 2.1±0.1 g/cm3 蒸汽压 Vapor Pressure 0.0±2.0 mmHg at 25°C 溶解度Solubility 性状 固体粉末,Power 储藏条件 Storage conditions -20°C 3 years年 4°C 2 years年 / In solvent溶液中:-80°C 6 months月 -20°C 1 month月 Ribavirin(CAS:36791-04-5)实验注意事项： 1.实验前需戴好防护眼镜，穿戴防护服和口罩，佩戴手套，避免与皮肤接触。 2.实验过程中如遇到有毒或者刺激性物质及有害物质产生，必要时实验操作需要手套箱内完成以免对实验人员造成伤害 3.实验后产生的废弃物需分类存储，并交于专业生物废气物处理公司处理，以免造成环境污染Experimental considerations: 1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment. 2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution. Tag:利巴韦林蒸汽压,利巴韦林合成,利巴韦林标准,利巴韦林应用,利巴韦林合成,利巴韦林沸点,利巴韦林闪点,利巴韦林用途,利巴韦林溶解度,利巴韦林价格,利巴韦林作用,利巴韦林结构式,利巴韦林用处,利巴韦林毒理性质 产品说明 利巴韦林(36791-04-5,Ribavirin) (ICN-1229) 是广谱的抗病毒药，可抑制HCV，HIVl，RSV等病毒 IntroductionRibavirin(利巴韦林,36791-04-5) (ICN229) is anantiviralagent against a broad spectrum of viruses includingHCV,HIVl, andRSV. Application1 Application2 Application3 Ribavirin description: 1.Ribavirin is a 1-ribosyltriazole that is the 1-ribofuranosyl derivative of 1,2,4-triazole-3-carboxamide. A synthetic guanosine analogue, it is an inhibitor of HCV polymerase and possesses a broad spectrum of activity against DNA and RNA viruses. It has a role as an antimetabolite, an antiviral agent, an antiinfective agent, an EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor and an anticoronaviral agent. It is a 1-ribosyltriazole, an aromatic amide and a monocarboxylic acid amide. 2.Ribavirin is a nucleoside analogue and antiviral agent used in therapy of chronic hepatitis C and other flavivirus infections. Ribavirin has not been associated with clinically apparent liver injury. 3.Ribavirin is a synthetic nucleoside analog of ribofuranose with activity against hepatitis C virus and other RNA viruses. Ribavirin is incorporated into viral RNA, thereby inhibiting viral RNA synthesis, inducing viral genome mutations, and inhibiting normal viral replication. 警示图 危险性 warning 危险性警示 Not available 安全声明 H303吞入可能有害+H313皮肤接触可能有害+H2413吸入可能对身体有害 安全防护 P264处理后彻底清洗+P280戴防护手套/穿防护服/戴防护眼罩/戴防护面具+P305如果进入眼睛+P351用水小心冲洗几分钟+P338取出隐形眼镜（如果有）并且易于操作,继续冲洗+P337如果眼睛刺激持续+P2393获得医疗建议/护理 备注 实验过程中防止吸入、食入，做好安全防护 Interactions Between Remdesivir, Ribavirin, Favipiravir, Galidesivir, Hydroxychloroquine and Chloroquine with Fragment Molecular of the COVID-19 Main Protease with Inhibitor N3 Complex (PDB ID:6LU7) U Potential benefits of combination of Nigella sativa and Zn supplements to treat COVID-19 Journal of herbal medicine 2020-10-01 Ribavirin therapy for severe COVID-19: a retrospective cohort study International journal of antimicrobial agents 2020-09-01 Clinical Trials of Repurposed Antivirals for SARS-CoV-2 Antimicrobial agents and chemotherapy 2020-08-20 Repurposing Drugs for COVID-19: An Approach for Treatment in the Pandemic Alternative therapies in health and medicine 2020-08-20 1.Retreatment of Hepatitis C with Consensus Interferon and Ribavirin After Nonresponse or Relapse to Pegylated Interferon and Ribavirin: A National VA Clinical Practice Study    Digestive Diseases and Sciences    2011 Abstract: (1)Background:Studies of the retreatment with consensus interferon (CIFN) and ribavirin (RBV) of hepatitis C virus (HCV)-infected patients who failed prior pegylated interferon alfa/ribavirin (PEG-IFN/RBV) have found quite variable efficacy and tolerability of this therapy . As such, CIFN/RBV use and efficacy in clinical practice were evaluated within the Department of Veterans Affairs (VA), the largest national, integrated system for HCV care. (2)Aims:The purpose of this study was to determine rates of sustained virologic response (SVR) and patterns of CIFN/RBV use in the VA. Methods included retrospective review of national VA data in HCV-infected patients who had previously failed ≥12 weeks of PEG- IFN/RBV and were prescribed CIFN/RBV between October 1, 2003 and September 30, 2006. (3)Results:A total of 597 patients met the study criteria. CIFN was primarily dosed as 15 mcg subcutaneously daily combined with standard doses of RBV. Mean treatment duration was 21 weeks; CIFN was discontinued within 4 weeks in 24%. Hematological growth factors were used in 49 %. Post-treatment viral loads were available in 385 patients. SVR to CIFN/RBV was achieved in 11%, and was significantly higher in prior PEG-IFN/RBV relapsers compared with nonresponders (31% vs. 6%, respectively; P <0.0001). A 2-log10 or greater drop in HCV RNA after 24 weeks of PEG-IFN/RBV was a predictor of subsequent SVR to CIFN/RBV. (4)Conclusions:CIFN/RBV was used frequently in clinical practice for retreatment of PEG-IFN/RBV. In this setting, early treatment discontinuation was common. Overall SVR was low, although response was significantly better in prior PEG-IFN/RBV relapsers and those who had a 2-log10 or greater decline than in nonresponders. 2.Blood cell, liver function, and response changes by PEG-interferon-α2b plus ribavirin with polaprezinc therapy in patients with chronic hepatitis C    Hepatology International    2008 Abstract: (1)Purpose:Zinc has been reported to ameliorate hematologic side effects and improve liver function. In addition to its various effects, zinc supplementation in chronic hepatitis C patients with genotype 1b of high viral load enhanced the response to interferon (IFN) monotherapy. This study was aimed at clarifying whether zinc could improve hematologic side effects, improve liver function, and enhance the response to therapy in patients with chronic hepatitis C treated with pegylated-interferon (PEG-IFN) plus ribavirin (RBV). (2)Methods:The 32 patients enrolled in the study were randomly divided into two groups: a PEG-IFN-α2b plus RBV with zinc group (PEG/RBV + zinc, n = 16) and a PEG-IFN-α2b plus RBV group (PEG/RBV, n = 16). HCV-RNA, serum zinc, ALT, white blood cell, red blood cell, platelet, and hemoglobin (Hb) levels were examined. (3)Results:Serum zinc levels were significantly higher in the PEG/RBV with zinc group than in the PEG/RBV without zinc group at 4, 8, and 12 weeks. No significant differences were observed in the clearance of HCV-RNA between the two groups. The outcome of the treatment was similar; results of laboratory examinations including ALT before, during, and after therapy revealed no significant differences between the two groups at any point in all items except serum zinc levels. A sustained virological response rate was observed in 50.0% in the PEG/RBV with zinc group and 43.8% in the PEG/RBV without zinc group, with no significant difference between the two groups. (4)Conclusions:The study demonstrated no evidence that zinc ameliorates hematologic side effects, improves liver function, and enhances the response to the therapy in chronic hepatitis C receiving PEG-IFN-α2b plus RBV. 对不起，暂无产品评价！